g***y
发帖数: 1025 | |
q********g
发帖数: 10694 | |
b*****h
发帖数: 783 | 3 sppi 现在position很强，以前担心FUSILEV的sale会在generic 恢复供应时大受影响，
现在情况相反，
第三季度的FUSILEV的sale已经增加到41M, sppi 的revenue 如能稳定在200m/year, 那
它的cap至少要1b。
【在 g***y 的大作中提到】
: 现金流和销售都有增加，11月蛮重要的。
|
j****0
发帖数: 799 | |
N*S
发帖数: 213 | |
j*****2
发帖数: 306 | 6 has a HUGE position at SPPI, any opinion of NOV 20's BIOSCAN REMOVE, and the
2 NDA file next year.
can this be next QCOR or even better??
【在 N*S 的大作中提到】
: sppi v5
|
g***y
发帖数: 1025 | 7 恩，不知道20号的结果会怎样，市场又太动荡，不敢下大赌注，不过按照他家CEO的水
平来看应该可以持有一段时间。
the
【在 j*****2 的大作中提到】
: has a HUGE position at SPPI, any opinion of NOV 20's BIOSCAN REMOVE, and the
: 2 NDA file next year.
: can this be next QCOR or even better??
|
C*G
发帖数: 7495 | |
g***y
发帖数: 1025 | 9 7:06AM Spectrum Pharma: FDA approves the removal of the Bioscan requirement
for ZEVALIN treatment (SPPI) 12.18 : Co, received approval from the FDA on
November 18, 2011 to remove the pre-treatment biodistribution evaluation
requirement using Indium-111 ZEVALIN imaging dose followed by a gamma scan
before administering the ZEVALIN therapeutic dose. This pre-treatment
biodistribution evaluation requirement is more commonly referred to as the
bioscan. |
N*S
发帖数: 213 | |
|
|
g******d
发帖数: 511 | |
j*****2
发帖数: 306 | 12 people too careful or smart never make big buck in stock market..
yes, maybe SPPI is overbought, but it is clearly hit the sweet spot for now..
buy and hold for next 2Q..
【在 N*S 的大作中提到】
: v555555
|
N*S
发帖数: 213 | 13 sold before FDA. still hold some share for free fun. |
v**********m
发帖数: 5516 | 14 错过这趟车了。
【在 g***y 的大作中提到】
: 现金流和销售都有增加，11月蛮重要的。
|
m*********n
发帖数: 6098 | |
N*S
发帖数: 213 | |
